Evidence map›Paper›PMID 42204876›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Scalable markers for early cognitive decline: Plasma p-tau217, subjective cognitive concerns, and digital testing: Results from the A4/LEARN studies.

Babak Khorsand, Devin Teichrow, Elham Ghanbarian, Lukai Zheng, S Ahmad Sajjadi, Crystal M Glover, Joshua D Grill, Laura A Rabin, Ali Ezzati

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Babak KhorsandDepartment of Neurology, University of California, Irvine, California, USA.ORCID https://orcid.org/0000-0002-1585-3909
Devin TeichrowDepartment of Neurology, University of California, Irvine, California, USA.
Elham GhanbarianDepartment of Neurology, University of California, Irvine, California, USA.
Lukai ZhengDepartment of Neurology, University of California, Irvine, California, USA.
S Ahmad SajjadiDepartment of Neurology, University of California, Irvine, California, USA.
Crystal M GloverDepartment of Neurology, University of California, Irvine, California, USA.
Joshua D GrillDepartment of Neurology, University of California, Irvine, California, USA.
Laura A RabinBrooklyn College and The Graduate Center - CUNY, Brooklyn, New York, USA.
Ali EzzatiDepartment of Neurology, University of California, Irvine, California, USA.ORCID https://orcid.org/0000-0003-1307-4589

Funding

The Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)U24AG057437 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul S. Aisen, RONALD C PETERSEN · 2018 to 2026
$198.4M
RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension StudyR01AG063689 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., SPERLING, REISA A. · 2019 to 2024
$30.8M
Validation of the Remote Cognitive Aging and Alzheimer’s Disease REsearch (R-CARE) Toolbox for Diverse PopulationsR01AG080635 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Ali Ezzati, Richard B. LIPTON · 2023 to 2026
$8.6M
Discovery and Trial Ready Cohort for Limbic Predominant Age Related TDP-43 Encephalopathy (TRC LATE)R01AG095017 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Ali Ezzati, Crystal M. Glover · 2025 to 2026
$6.3M
Predictive analytics for cognitive decline and Alzheimer’s diseaseK23AG063993 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI EZZATI, ALI · 2020 to 2024
$984k
Accelerating Medicines PartnershipAvid and CogstateEli Lilly and CompanyGHR FoundationNational Institutes of Health/National Institute on AgingNIA NIH HHS K23 AG063993NIA NIH HHS R01 AG063689NIA NIH HHS R01 AG080635NIA NIH HHS R01 AG095017NIA NIH HHS U19 AG010483NIA NIH HHS U24 AG057437public-private philanthropic partnership
6 · The paper itself

Abstract

introductionAmyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers confirm Alzheimer's disease (AD) pathology but are impractical for large-scale screening. Plasma phosphorylated tau at threonine 217 (p-tau217), subjective cognitive concerns, and computerized cognitive testing are non-invasive, scalable, and feasible to implement in large populations. We assessed their separate and combined predictive value for cognitive decline.

methodsWe analyzed 1064 cognitively unimpaired adults (ages 65-85 years) from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4; amyloid-positive) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN; amyloid-negative) studies. Baseline assessments included apolipoprotein E (APOE) ε4 status, hippocampal volume, amyloid PET, plasma p-tau217, Cognitive Function Index (CFI), and Cogstate Computerized Battery (CCB). Cognitive impairment was defined as conversion from a Clinical Dementia Rating Global Score (CDR-GS) of 0 to ≥0.5 over 240 weeks.

resultsDuring the follow-up, 34.1% developed cognitive impairment. Higher p-tau217, higher CFI, and lower CCB were associated with higher odds of converting to CDR-GS >0 across all cohorts. DISCUSSION: P-tau217, CFI, and CCB each independently predict cognitive decline, offering practical, non-invasive tools for early AD risk stratification and trial enrichment.

Indexed as

Alzheimer DiseaseCognitive Dysfunctiontau ProteinsAgedAged, 80 and overBiomarkersFemaleHumansLongitudinal StudiesMaleNeuropsychological TestsPositron-Emission TomographyBiomarkersMAPT protein, humantau ProteinsAlzheimer's diseasecognitive declinedigital biomarkersplasma biomarkerssubjective cognitive concerns

Identifiers

PMID42204876
PMCPMC13240426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.